

1    **Title Page**

2    **Integrating Lung Tissue and Lavage Proteomes Reveals Unique Pathways in Allergen-**

3    **Challenged Mice**

4

5    Thomas H Mahood<sup>1,2,3,6</sup>, Christopher D Pascoe<sup>1,2,3,6</sup>, Aruni Jha<sup>1,2,3,6</sup>, Sujata Basu<sup>1,2,3,6</sup>, Peyman

6    Ezzati<sup>4</sup>, Victor Spicer<sup>4</sup>, Neeloffer Mookherjee<sup>2,3,4,5,6</sup>, Andrew J Halayko<sup>1,2,3,6</sup>

7

8    <sup>1</sup>*Department of Physiology & Pathophysiology, University of Manitoba, Winnipeg, Manitoba,*

9    *R3E 0J9, Canada*

10    <sup>2</sup>*DEVOTION Network, Winnipeg, Manitoba, Canada*

11    <sup>3</sup>*Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg,*

12    *Manitoba, R3E 3P4, Canada*

13    <sup>4</sup>*Manitoba Centre for Proteomics and Systems Biology, Department of Internal Medicine,*

14    *University of Manitoba, University of Manitoba, Winnipeg, Manitoba, R3E 3P4, Canada*

15    <sup>5</sup>*Department of Immunology, University of Manitoba, Winnipeg, Manitoba, R3E 0T5, Canada*

16    <sup>6</sup>*on behalf of the Canadian Respiratory Research Network,*

17    *<http://respiratoryresearchnetwork.ca/>, Ottawa, Ontario, Canada*

18

19    **Running Title:** Lung Tissue and Lavage Proteome

20

21 **Abstract**

22 Independent proteomic analysis do not capture the biological interactions between the tissue and  
23 extracellular biological compartments when examined in isolation. To address this, we analyzed  
24 and compared the proteome from lung tissue and from bronchoalveolar lavage fluid (BALF) of  
25 individual allergen-naïve and allergen-challenged BALB/c mice, a common pre-clinical model  
26 of allergic asthma. Collectively, we quantified 2,695 proteins from both tissue and BALF of  
27 allergen-naïve and -exposed mice. We created an integrated dataset to examine tissue-BALF  
28 proteome interactions. Multivariate analysis identified this Integrated-Tissue-BALF (ITB)  
29 dataset as being distinct from either the lung tissue or the BALF dataset. Pathway and network  
30 analysis of the ITB dataset uncovered protein hubs that span both the tissue and BALF, but are  
31 not significantly enriched in either sample dataset alone. This work reveals that by combining  
32 individual datasets provides insight about protein networks that integrate biology in lung tissue  
33 and the airway space in response to allergen challenge.

34

35 **Keywords:** bronchoalveolar lavage / asthma / bioinformatics / allergen / proteomics

36

37 **Introduction**

38 At the organ level, the biological underpinnings of chronic inflammatory disease involves  
39 complex molecular interplay between local structural cells, recruited cells and the extracellular  
40 mediators that they each release. Such is the case for asthma, a chronic disorder of the airways  
41 that requires new therapies to fully control steroid-resistant inflammation. Mice challenged with  
42 allergen are a mainstay for pre-clinical asthma research. A common approach is to use house  
43 dust mite (HDM) as an aeroallergen as it is clinically relevant to human disease, and represents a  
44 complex stimulus that includes multiple immunogens and stressors, including fungal spores,  
45 bacterial endotoxins, lipid-binding proteins and proteases (Calderón *et al.* 2015; Choopong *et al.*  
46 2016). Repeated HDM challenge induces pathophysiologic symptoms that are hallmarks of  
47 human asthma (Jha *et al.* 2018), however the scope and complexity of the interplay between lung  
48 cells, recruited inflammatory cells, extracellular mediators of autocrine and paracrine  
49 significance, and the integrated signaling pathways that lead to pathobiology and can determine  
50 the efficacy of pre-clinical asthma therapeutics, has not been refined as a systems biology model.

51 To understand complex and integrated disease mechanisms, a number of omics  
52 technologies have been employed, including proteomics. Some studies examine the proteome of  
53 individual biological compartments, including airway spaces - collected as bronchoalveolar  
54 lavage fluid (BALF) or sputum - and lung tissue from asthmatic patients and murine models of  
55 the disease (Wu *et al.* 2005; O'Neil *et al.* 2011; Burg *et al.* 2018). These studies have been  
56 important for endotyping patients and animal models, identifying biomarkers of disease and  
57 providing direction for new therapeutic strategies. However, analysis of these biological  
58 compartments in isolation does not enable identification of integrated molecular networks that  
59 that are critical for disease expression. Thus, despite some advances in identifying extracellular  
60 biomarkers or tissue response networks, understanding the molecular systems that are affected  
61 by the interaction between secreted proteins in the lung and the pathways that are regulated in the

62 resident cells of the lung tissue has not been fully established.

63 To address this, we used unbiased proteomic analysis to establish a molecular signature

64 in the lung through integrated analysis of matched lung tissue and BALF, and comparing

65 allergen-naïve and HDM-challenged mice. We found that inhaled HDM challenge induces

66 relatively distinct proteome signatures in lung tissue and BALF. Using a bioinformatic approach,

67 we developed an Integrated-Tissue-BALF (ITB) proteome that uncovers signaling networks that

68 are not evident from proteomic datasets of lung tissue and BALF individually.

69

## 70 **Results**

### 71 ***Lung function & differential cell count analysis***

72 For all mice, we characterized hallmark pathophysiological features that developed as a

73 result of repeated HDM challenge for two weeks in 6-8-week-old female BALB/c mice. We

74 performed lung function and differential immune cell count analyses to assess the phenotype of

75 individual animals (Supplemental Figure S1). HDM challenge resulted in features that are

76 consistent with human asthma, including increased methacholine-induced airway resistance

77 (adjusted p-value,  $p.\text{adj} \leq 0.001$ ), tissue elastance ( $p.\text{adj} \leq 0.001$ ) and tissue resistance ( $p.\text{adj} \leq$

78 0.001) at 50 mg/mL methacholine (two-way nested ANOVA with Tukey's multiple comparison

79 and FDR correction,  $n = 6$ ) (Supplemental Figure S2A). Differential counting of BALF immune

80 cells revealed that HDM challenge triggered their accumulation, including eosinophils and

81 neutrophils (Supplemental Figure S2B).

82

### 83 ***Lung tissue, BALF and Integrated-Tissue-BALF proteomes have distinct profiles***

84 In total, our proteomic analysis of lung tissue and BALF samples across all mice, yielded

85 2695 protein identifications (IDs). We obtained  $1595 \pm 155$  protein IDs from lung tissue and  $581 \pm 201$  (mean  $\pm$  SD) protein ID's from BALF (Supplemental Figure S3A,B).

87 HDM exposure increased the absolute number of proteins in the lung tissue by 16 %  
88 (357), and by 53 % (621) in the BALF. The relative proportion of protein ID's that are unique to  
89 tissue decreased from 78.4 % to 61.4 % after HDM exposure. In contrast, the proportion of  
90 unique BALF proteins was relatively unchanged by HDM challenge (29.0 % and 28.2 %,  
91 respectively). The relative proportion of protein ID's that are shared between the BALF and lung  
92 tissue increased from 19.7 % to 33.47 % after HDM exposure (Figure 1A).

93 To confirm that secreted proteins are enriched in BALF, we characterized the protein  
94 ID's using Uniprot annotation keywords. Of the proteins that could be annotated as "secreted"  
95 we found that 29 % and 81 % of the protein ID's were classified as tissue and BALF  
96 respectively. Therefore, the BALF is enriched in secreted proteins by 279 %, compared to lung  
97 tissue. Of the proteins that could be annotated as "transmembrane" we found that 71 % of  
98 proteins were associated with the lung tissue proteome, compared to only 19 % of BALF  
99 proteins. Therefore, the tissue is enriched in cell-associated proteins by approximately 373 %,  
100 compared to BALF.

101 Using the normalized log2 protein expression values, we calculated z-scores (on a  
102 sample-by-sample basis) to assess the relative contribution of protein signatures from the tissue  
103 or BALF on a common scale. Once calculated for each sample, z-scores for HDM exposure were  
104 corrected by subtracting each sample by the mean z-score of the naïve samples. To assess the  
105 integrated biological contribution of BALF and tissue proteomes from HDM challenged mice, z-  
106 scores from individual datasets were summed. This Integrated-Tissue-BALF (ITB) dataset  
107 includes 2,695 protein IDs.

108 To investigate if the proteome from lung tissue, BALF and ITB datasets are distinct we  
109 performed Partial Least Squares Discriminant Analysis (PLSDA). Figure 1B shows that the  
110 individual 95 % confidence interval ellipse for lung tissue, BALF and ITB proteome are  
111 segregate. Variance Importance in Projection (VIP) scoring identified the proteins that are the

112 most significant discriminators of the three datasets. We identified 30 targets that had a VIP  
113 score  $\geq 2.37$ . Of these, eight proteins (Rab1a, Fn1, Sftpa1, Clic4, Npepps, Iqgap1, Flna, Actr3)  
114 comprised a group with the highest VIP scores, positioned above a natural inflection point set by  
115 Actr3 (VIP = 2.64) (Figure 1C). We used matched lung tissue and BALF from individual mice,  
116 thus we were not only able to discriminate proteins that were changed after HDM challenge, but  
117 also detected those that were enriched or diminished specifically in BALF or lung tissue. For  
118 example, the VIP Score projection plot (Figure 1C) reveals that fibronectin-1 (Fn1) was  
119 diminished in tissue (z-score -0.816), enriched in BALF (z-score 0.91), and appeared to be  
120 unchanged if considered in the ITB proteome (z-score 0.093). This suggests that the change in  
121 protein abundance in one biological compartment, may be a reflection of change in another  
122 compartment.

123

#### 124 ***Unique and significantly enriched proteins from tissue, BALF and ITB proteomes***

125 We identified 1,818 proteins unique to lung tissue and BALF datasets across both the  
126 HDM challenged and allergen-naïve mice. These are revealed in Figure 2 by plotting individual  
127 protein z-scores (assigning a z-score of -4 for any absent value) from the naïve and HDM  
128 treatments across the lung tissue, BALF, and ITB datasets. This approach classified proteins in  
129 lung tissue, BALF, and ITB datasets as being: 1) unique to HDM-challenge (located along y-axis  
130 of figure inserts in panels 2A-C); 2) unique to allergen-naïve (located along the x-axis of figure  
131 inserts in panels 2A-C); or, 3) common to HDM-challenged and allergen-naïve mice (located  
132 within the ellipse regions of figure inserts in panels 2A-C). Of the proteins that are unique to  
133 HDM exposed mice, we detected 529 in lung tissue, 654 in BALF, and 699 in the ITB dataset.  
134 For the proteins identified only in allergen-naïve mice, 174 existed in lung tissue, 34 in BALF,  
135 and 171 in the ITB dataset. Of the proteins that were common in samples from HDM challenged  
136 and allergen-naïve mice, we detected 1671 in tissue, 534 in BALF, and 1825 in the ITB dataset.

137         Using a statistical analysis of microarrays (SAM) workflow on the proteins that were  
138         common to samples from allergen-naïve and HDM-challenged mice, we identified those proteins  
139         that were significantly enriched or diminished in tissue (124 enriched; 134 diminished), BALF  
140         (92 enriched; 56 diminished), and the ITB dataset (51 enriched; 35 diminished). These proteins  
141         are highlighted in the volcano plots depicted in Figure 2A-2C. Of these differentially regulated  
142         proteins, a number were uniquely affected in lung tissue or BALF, while only a small number  
143         emerged as being differentially regulated exclusively in the ITB dataset.

144         To identify proteins that are common in the lung tissue and BALF proteomes, but  
145         differentially regulated in each dataset by HDM exposure, we plotted the average BALF z-score  
146         versus the average lung tissue z-score for each protein (Figure 2D). Of 27 proteins *enriched in*  
147         *tissue, but diminished in the BALF proteome*, 10 were confirmed to be significantly enriched  
148         (Benjamini-Hochberg multiple comparison correction; Limma R package,  $p.\text{adj} \leq 0.05$ ) (Table  
149         1). Reactome pathway analysis using the 10 most significantly enriched proteins, identified  
150         glutathione synthase deficiency as the most significantly enriched pathway ( $p.\text{adj} = 6.43 \times 10^{-4}$ ),  
151         (Figure 2E). Of the 200 proteins *enriched in BALF but diminished in the lung tissue proteome*,  
152         141 were confirmed to be significantly enriched (Benjamini-Hochberg multiple comparison  
153         correction; Limma R package,  $p.\text{adj} \leq 0.05$ ) (Table 2). InnateDB pathway analysis from these  
154         141 proteins identified platelet degranulation as the most significantly enriched pathway ( $p.\text{adj} =$   
155          $8.17 \times 10^{-11}$ ) (Figure 2F).

156

### 157         ***Unique biological processes induced by allergen challenge in tissue, BALF and ITB***

158         Using InnateDB we identified biological responses that are significantly altered by HDM  
159         challenge as represented in the lung tissue, BALF, and ITB datasets (Figure 3). In the lung tissue  
160         proteome a number of dataset-unique processes were induced. The top five statistically  
161         significant processes were: small molecule metabolism ( $p.\text{adj} = 1.04 \times 10^{-10}$ ); antigen processing

162 and presentation ( $p.\text{adj} = 2.19 \times 10^{-9}$ ); activation of PKC ( $p.\text{adj} = 5.82 \times 10^{-7}$ ); activation of the  
163 adaptive immune system ( $p.\text{adj} = 6.57 \times 10^{-7}$ ); and, platelet degranulation ( $p.\text{adj} = 9.50 \times 10^{-7}$ )  
164 (Figure 3A).

165 In BALF several dataset-unique biological processes were also evident, with the top five  
166 responses being: cell cycle arrestment through degradation of Cyclin D ( $p.\text{adj} = 5.39 \times 10^{-21}$ );  
167 dysfunctional binding of  $\beta$ -catenin through altered AMER1 and APC ( $p.\text{adj} = 6.07 \times 10^{-21}$ );  
168 altered WNT signaling through TCF7L2 frameshift mutations ( $p.\text{adj} = 6.07 \times 10^{-21}$ ); and, GSK3  
169 stabilization and nuclear localization through  $\beta$ -catenin mutations ( $p.\text{adj} = 6.07 \times 10^{-21}$ ) (Figure  
170 3B).

171 In the ITB dataset we identified 19 pathways for which tissue was the major contributing  
172 factor (Figure 3C). The top 3 most significant pathways included, trafficking and processing of  
173 endosomal TLR ( $p.\text{adj} = 1.43 \times 10^{-4}$ ), antigen processing and presentation ( $p.\text{adj} = 4.85 \times 10^{-4}$ ),  
174 and cross-presentation of particulate exogenous antigens (phagosomes) ( $p.\text{adj} = 4.97 \times 10^{-4}$ ). We  
175 also identified 6 pathways for which BALF was the major contributing factor in the ITB  
176 proteome ( $p.\text{adj} \leq 0.05$ ) (Figure 3D), with the top three being antigen processing (ubiquitination  
177 & proteasome degradation,  $p.\text{adj} = 2.22 \times 10^{-13}$ ), recycling pathway of L1 ( $p.\text{adj} = 3.14 \times 10^{-7}$ ),  
178 and post-chaperonin tubulin folding pathway ( $p.\text{adj} = 2.35 \times 10^{-5}$ ).

179 We identified 11 pathways that were only significantly enriched after the proteome  
180 datasets from the lung tissue and BALF were integrated, thus were unique to the ITB dataset  
181 ( $p.\text{adj} \leq 0.05$ ) (Figure 3E). The top processes included: endosomal transport (ESCRT) ( $p.\text{adj} =$   
182 0.0217); phospholipid metabolism ( $p.\text{adj} = 0.0332$ ); glycerophospholipid metabolism ( $p.\text{adj} =$   
183 0.0334); synthesis of IP3 and IP4 in the cytosol ( $p.\text{adj} = 0.0352$ ); and, degradation of the ECM  
184 ( $p.\text{adj} = 0.0353$ ).

185

186 ***Disparate protein-protein interactions in BALF and tissue datasets***

187 The underpinnings of the biological processes affected by allergen challenge in lung  
188 tissue and BALF proteome datasets lies in the protein interaction hubs and networks that are  
189 engaged. To decipher these pathways we used NetworkAnalyst and identified the most  
190 significantly induced networks, based on the number of first order protein-protein interactions,  
191 but independent of the fold-change in abundance of individual proteins. We extracted the top 3  
192 protein-protein interaction hubs in the individual datasets for the lung tissue and BALF datasets  
193 (Figure 4). In lung tissue, the top three protein interaction hubs were for Hdac1, Ctnnb1 and  
194 Smarca4 (Figure 4A). Collectively, these lung tissue protein interaction hubs create a network  
195 associated with adherens junctions interactions ( $p.\text{adj} = 7.44 \times 10^{-5}$ ). In the BALF dataset, the top  
196 three first order interaction hubs were Akt1, Dnm1 and Csf1r (Figure 4B). The biological  
197 pathways associated with these interaction hubs were distinct from those of lung tissue proteome.  
198 The resulting network formed from these three BALF hubs was associated with immune system  
199 pathways ( $p.\text{adj} = 2.00 \times 10^{-14}$ ).

200 To assess the impact of integrating the lung tissue and BALF datasets on the top three  
201 pathways predicted from each dataset individually, we reassessed the degree of networking for  
202 each of these six hubs in the ITB dataset (Figure 4C). Dataset integration increased the average  
203 number of first order protein-protein interactions by 2.83 per hub (a 7.7 % increase). For the top  
204 interaction nodes first identified in the lung tissue dataset alone (Figure 4A), the biological  
205 pathways associated to each protein hub were unchanged in the ITB dataset (Figure 4C).  
206 However, for the most significant interaction hubs first identified in the BALF dataset alone  
207 (Akt1, Dnm1 and Csf1) (Figure 4B), the increased number and diversity of protein-protein  
208 interactions created in the ITB dataset changed the biological process predicted from “immune  
209 response” to “adaptive immune system pathways” ( $p.\text{adj} = 9.70 \times 10^{-13}$ ). Finally, for the ITB  
210 dataset, “developmental biology” ( $p.\text{adj} = 1.49 \times 10^{-13}$ ) emerged as the most significantly  
211 associated biological pathway when we assessed the integration of the six interaction hubs

212 identified in lung tissue and BALF proteomes individually. These data demonstrate the diversity  
213 of insight that can be obtained from individual biological compartments of the lung, and from an  
214 ITB dataset that includes both components.

215

## 216 ***Protein-protein interaction enrichment in the Integrated-Tissue-BALF dataset***

217 We catalogued the new interactions that emerge in the ITB dataset to explore how  
218 unifying lung tissue and BALF datasets affects the scope of the predicted protein-protein  
219 interactions (Table 3A and 3B). For this purpose, we developed a combined dataset that included  
220 1,346 proteins unique to the lung tissue, and 333 proteins unique to the BALF proteome after  
221 HDM challenge. In total this comprised 1,679 proteins and is hereafter called the “Unique-to-  
222 Combined” (UtC) dataset. The UtC dataset is distinct from the ITB dataset as it *excludes* the 845  
223 proteins that we identified in both lung tissue and BALF. This enables more direct critical  
224 assessment of the potential integration of networks between compartments. We limited our  
225 analysis of protein hubs that had at least five first order interactions in the UtC dataset, and  
226 assessed the number of new first order interactions that emerged for lung tissue- or BALF-  
227 specific proteins.

228 First order interactions specifically identified for BALF-specific proteins were enriched  
229  $42.1 \pm 21.8\%$  (range of 12-85%) in the UtC dataset (Table 3A), whereas protein hubs identified  
230 from the lung tissue-specific proteome were only enriched  $20.4 \pm 5.8\%$  (range of 14-33%) (Table  
231 3B). To more clearly decipher the impact of combining unique to-lung tissue or -BALF proteins  
232 we determined first order protein interaction networks in the UtC dataset using the Reactome  
233 module within NetworkAnalyst. To streamline our analysis, we specifically examined the effects  
234 on networks developed from the top three protein hubs that emerged from unique to-lung tissue  
235 data, and top four unique-to-BALF dataset (the 3<sup>rd</sup> and 4<sup>th</sup> ranked hubs had identical enrichment  
236 scores).

237 For hubs involving lung tissue-unique proteins, Hgs, Arhgef7 and Akap8 were most  
238 enriched by integrating BALF proteins (Figure 5A), however there was limited interaction  
239 evident between individual hubs. The network of these three interaction hubs identified  
240 “signaling by interleukins” (p.adj = 1.49 x10<sup>-13</sup>) as the most significantly associated biological  
241 process. For hubs formed by unique-to-BALF proteins, all hubs were interconnected, for  
242 example, two independent connections were evident between Casp7 and Spp1 (Figure 5B). The  
243 network formed by the four BALF-unique proteins (Dnm1, Tceb1, Spp1 and Casp7) identified  
244 “axon guidance” (p.adj = 0.0224) as the most significantly associated biological process.

245 To further assess the impact of integrating unique-to-lung tissue and -BALF proteins in  
246 the UtC, we reassessed the degree of networking for each hubs formed by lung tissue- and  
247 BALF-unique proteins (Figure 5C). In the UtC dataset we identified a large number of new  
248 connections between individual proteins and between protein hubs, highlighting the strong  
249 potential for protein-protein interactions between the lung tissue and BALF compartments. The  
250 resulting increased number of protein-protein interactions at these hubs in the UtC dataset  
251 predicted new biological functions. For example, new interactions in the UtC dataset for the lung  
252 protein hubs (Hgs, Arhgef7 and Akap8) changed pathway association from signalling by  
253 interleukins (Figure 5A) to being “SMC binds to IAPs” (p.adj = 7.24x10<sup>-5</sup>). The effect of data  
254 integration in the UtC dataset also changed the biological function predicted for unique-to-BALF  
255 protein hubs (Dnm1, Tceb1, Spp1 and Casp7), resulting in a prediction for EGFR  
256 downregulation (4.31x10<sup>-7</sup>). Together these results suggest that the UtC dataset enriches the  
257 number of protein-protein interactions within individual networks. This enrichment enhances  
258 interconnectivity of proteins between biological compartments of the lung and refines that  
259 predicted biological significance of these networks.

260

261 **Discussion**

262 Murine models of allergic airways inflammation employ inhaled aeroallergen such as  
263 HDM to support preclinical and discovery research. Asthma pathobiology involves recruited  
264 inflammatory cells and lung structural cells that interact to define pathobiological processes. In  
265 this study, we used label-free proteomics and multivariate bioinformatics to describe and  
266 compare the molecular interactome in BALF and lung tissue specimens from HDM challenged  
267 mice. We used matched samples from a cohort of individual mice for this process, and in so  
268 doing have been able to discriminate responses in tissue and the airspaces, and through *in silico*  
269 re-integration, predict the interactions between the lung tissue and the BALF. We demonstrate  
270 that the proteome between the lung tissue and BALF is significantly different in mice, with each  
271 sample exhibiting unique proteins that are differentially changed by HDM challenge, revealing  
272 unique biological responses in each. We generated an Integrated-Tissue-BALF dataset to enable  
273 network analysis that reveals points of interaction between lung tissue and airspace proteins and  
274 pathways. Our study provides a platform that reveals the scope and limits of biological insights  
275 that can be obtained from lung tissue or BALF sample proteins alone and offers the potential to  
276 interrogate network interactions between the lung tissue and extracellular airway space during  
277 allergen challenge.

278 Most ‘omics’ bases studies, including proteome profiling, usually focuses on what is  
279 enriched/depleted or up-/down-regulated in a treatment in a tissue or individual bio-sample,  
280 compared to a control. Though this is insightful, it is often not possible to distinguish whether  
281 proteins are from cells, released by cells, or both in a tissue. The source of the proteins can be  
282 predicted using most available informatics tools, though their annotation is completely based on  
283 if that protein resides within the tool being used. In this study we demonstrate that investigating  
284 individual compartments of one organ, the lung, then integrating them post hoc can provide  
285 clarity about the source of the biological processes in the whole system. In this study we

286 developed a methodology to integrate proteomes from two separate, but biologically linked  
287 compartments. To enable this, we sampled lung tissue and airway lavage from each animal to  
288 separate sample-unique proteomes. We also used untargeted proteomics to provide a broad,  
289 unbiased survey of changes in BALF and lung tissue pre- and post- allergen challenge. Once  
290 proteome data was acquired we employed non-biased statistics to integrate the two datasets,  
291 specifically using z-score analysis that normalized for differences in total protein abundance in  
292 different samples. This approach allowed us to consider the biological interaction between the  
293 tissue and airspace compartments of the murine lung.

294  
295 We used an untargeted approach to compare the lung tissue and BALF proteomic  
296 changes which occur during repeated aeroallergen challenge. To do this, we collected animal-  
297 matched samples, meaning that the lung tissue proteome was determined in lungs after BALF  
298 was collected; as such, the protein fingerprint linked to secretory function of egressed  
299 inflammatory cells and structural cells is enriched in BALF, and diminished in the lung tissue  
300 proteome. To create a ‘pseudo whole lung’ proteome, we integrated individual datasets post hoc  
301 to create the ITB dataset, rather than collecting a proteome dataset from lungs that had not  
302 undergone BALF collection. Our design was necessary to enable discrimination of unique effects  
303 in the lung tissue and BALF compartments. Importantly, prior to proteomic analysis, BALF  
304 samples were centrifuged to remove immune cells for counting and differential analysis. Thus,  
305 our integrated dataset does not capture intracellular proteins from immune cells that had  
306 migrated into the airway space.

307

### 308 ***Biological pathways in the lung tissue proteome***

309 The lung tissue dataset had a 447 % more unique protein ID’s compared to BALF. When  
310 examining the top 10 unique tissue pathways, the immune system was found to be a significant  
311 biological signature. These pathways were associated with an acute immune response signature,

312 specifically allergen detection and antigen processing/presentation. This likely reflects the  
313 significant immune cell population that resides in the airway wall and the lung interstitium, but  
314 may also include the small number of cells remaining in the pulmonary circulation. Upon  
315 allergen challenge, epithelial, mesenchymal and resident immune cells are stimulated and secrete  
316 cytokines, chemokines and other pro-inflammatory mediators that have auto- and paracrine  
317 effects on structural cells such as fibroblasts and airway smooth muscle cells (Halayko and  
318 Amrani, 2003). These cells have a significant immunomodulatory capacity, and also secretion  
319 mediators to orchestrate local inflammation and epithelial cell biology. This promotes  
320 inflammatory and fibro-proliferative processes in lung tissue that are hallmarks of the response  
321 to allergen exposure (Halayko and Amrani, 2003). An immune signature in lung tissue and  
322 BALF has been described to represent a Th2-polarized response after challenge with inhaled  
323 HDM (Piyadasa *et al.* 2016), and as we confirmed in the current study, includes significant tissue  
324 infiltration by eosinophils and neutrophils. Together this data suggests that immune responses in  
325 lung tissue likely reflect the coordinated activity of resident structural cells and immune cells that  
326 has infiltrated lung tissue.

327

### 328 ***Biological pathways in the BALF proteome***

329 In our BALF proteomic dataset, we detected a strong biosignature for pathways involving  
330  $\beta$ -catenin, which has recognized roles in regulation of cell-cell adhesion and gene transcription  
331 (Baarsma *et al.* 2013; Koopmans *et al.* 2017). Within the airways, epithelial barrier function is  
332 maintained through adherens junctions in which  $\beta$ -catenin interacts with its neighbouring  
333 partners  $\alpha$ -catenin, p120 and e-cadherin. Through repeated allergen exposure, e-cadherin is  
334 down-regulated to disrupt  $\beta$ -catenin function and barrier repair signaling through epithelial-  
335 growth-factor-receptor mediated signaling (Heijink *et al.* 2007). This is also associated with the  
336 secretion of Th2 immune mediators (Heijink *et al.* 2007), and local cell damage and necrosis in

337 response to HDM challenge (Chan *et al.* 2016; O'Neil *et al.* 2011; Petta *et al.* 2017). Our  
338 proteome analysis indicates that epithelial cell denudation and barrier disruption during allergen  
339 challenge contributes significantly to molecular mechanisms that can be detected in BALF.

340

#### 341 ***Biological pathways in the Integrated-Tissue-BALF proteome***

342 We identified several biological mechanisms that emerge as significant processes only  
343 after integrating the proteome of the lung tissue and BALF. This appears to arise from an  
344 enrichment of the number of pathway-specific proteins, and the additive effect on the abundance  
345 of proteins that are common to lung tissue and BALF. As an example, the ITB dataset uniquely  
346 reveals processes for generating multi-vesicular bodies that both target protein for ubiquitination  
347 leading to turnover in lysosomes (Karim *et al.* 2018), and for the biogenesis of extracellular  
348 vesicles (Colombo *et al.* 2013). This specifically relates to proteins associated with multiunit  
349 Endosomal Sorting Complexes Required for Transport (ESCRT), including endosomal sorting  
350 protein Chmp6, and vesicle sorting (Vps4b) and trafficking (Vta1) proteins from lung tissue, and  
351 ubiquination proteins (Tonsoku Like, DNA Repair Protein (Tonsl) and ubiquitin B) and vacuole  
352 sorting proteins (Vps25 and Vps4a) from BALF. Interestingly, ESCRT is associated with  
353 secretion of inflammatory mediators and protein turnover, key processes in inflammation and  
354 tissue remodeling processes (Kulshreshtha *et al.* 2013; Karim *et al.* 2018).

355 Another example of a biological pathway that is significantly enriched only in the ITB  
356 dataset relates to the degradation of the extracellular matrix (ECM). BALF included a number of  
357 ECM proteins, including collagen (Col17a1) and fibronectin (Fn1). Lung tissue included  
358 multiple enzymes that modulate ECM homeostasis, such as nicastrin (Ncstn, a member of the  
359 gamma secretase complex), cathepsins G, L1, and S, neutrophil elastase (Elane), and matrix  
360 metalloproteinase-9 (MMP9). The emergence of both ESCRT signaling and ECM turnover only  
361 after combining the lung tissue and BALF proteomes suggests that mechanisms that define

362 interactions between lung tissue cells and the lung airspace are underrepresented in the  
363 individual proteomes for lung tissue or BALF.

364 To better understand how the proteins in BALF and lung tissue may influence the  
365 biological activity in each compartment we created a subset of ITB data that merged only those  
366 proteins that were unique to either BALF or lung tissue. The so-called, UtC enabled  
367 identification of protein hubs in BALF or lung tissue that could be most significantly influenced  
368 by signals in the other compartment. Through this approach predictive assessment of pathways  
369 that link biological processes in lung tissue and the airspace compartment is possible. In our  
370 analysis we showed that a unique lung tissue protein network predicted to support signaling by  
371 interleukins, was refined to one associated with SMAC binding to IAPs, which releases caspases  
372 that mediate apoptotic cell death (Du *et al.* 2000). In parallel, a unique BALF protein network  
373 predicted to support axonal guidance, was refined to one associated with EGFR down regulation  
374 on the basis of the influence of lung tissue proteins. Furthermore, in the UtC, developmental  
375 biology emerged as the primary response pattern, a result that was not predicted from lung tissue  
376 or BALF proteome datasets individually. Overall integrating lung tissue and BALF proteomes  
377 strengthens independent connectedness and yields new biological insight for the whole lung in  
378 response to allergen exposure.

379 The interpretation of our study is limited by a number of factors. Though we carefully  
380 controlled our collection methods to reduce variability and decrease damaging effects of BALF  
381 collection on tissue cells, but we cannot discount that BALF samples included a small fraction of  
382 proteins from damaged cells. Our samples were only collected at a single time point (48 hours  
383 after final allergen challenge), a strategic choice, as this represents the time when lung  
384 dysfunction is greatest, including airway hyperresponsiveness. Thus, our work provides only a  
385 snapshot of the dynamics of proteome response to a specific allergen challenge, and future  
386 studies looking at temporal patterns in response to HDM and other allergens are needed for a

387 more robust resource to delineate the molecular responses that contribute to lung inflammation  
388 and dysfunction in allergen-challenge mouse models.

389

390 ***Conclusion***

391 We characterized the proteome of lung tissue and BALF from HDM-challenged mice that  
392 mimic allergic asthma pathophysiology. Using matched samples from individual animals, our  
393 work reveals that lung tissue and BALF proteomes are diverse, and that integrating both datasets  
394 reveals additional novel biological processes and protein interaction hubs. This work provides a  
395 resource and approach for identifying new proteins and pathways, and a basis to interrogate  
396 interactions between sample compartments to identify mechanisms for airways pathophysiology  
397 and, perhaps, new targets for developing therapeutic approaches.

398

399 **Methods**

400

401 ***Animal experiments***

402 ***(a) Murine HDM allergen challenge***

403 All animal experiments were planned and performed following the approved protocols  
404 and guidelines of the animal ethics board at the University of Manitoba. Female, BALB/c mice  
405 (6-8 weeks,  $n = 3$ ) were intranasally challenged with HDM (25  $\mu$ g per mouse, in a total volume  
406 of 35  $\mu$ L saline) five times a week for two weeks (Supplemental 1). Our HDM formulation  
407 consisted of HDM extract (Greer Labs, Lenoir, NC) prepared in sterile phosphate buffered saline  
408 (PBS, pH 7.4; Life Technologies, Waltham, MA). The HDM extract we used contained 36,000  
409 endotoxin units (EU) per vial (7877 EU/mg of protein or 196.9 EU/dose) containing 4.9 % Der p  
410 1 protein.

411

412 ***(b) Lung function, inflammatory differential cell counts and sample collection***

413 Lung function was performed 48 h after the last HDM challenge. Mice were anesthetized  
414 with sodium pentobarbital (90 mg/kg), given intraperitoneally and tracheotomized with a 20-  
415 gauge polyethylene catheter. The polyethylene catheter was connected to a flexiVent small  
416 animal ventilator (Scireq, Montréal, Canada) and mice were mechanically ventilated with a tidal  
417 volume of 10 mL/kg body weight, 150 times/min. Forced oscillation technique and positive end  
418 expiratory pressure of 3 cm·H<sub>2</sub>O was used for the entire study. Mice were subjected to an  
419 nebulized methacholine (MCh) challenge (0 to 50 mg/mL) to assess concentration dependent  
420 response of the respiratory mechanics. Measures of newtonian resistance (R<sub>n</sub>), peripheral tissue  
421 damping (G) and tissue elastance (H), and total resistance (R) were collected. Values for each  
422 parameter were calculated as the peak of all 12 perturbation cycles performed after each MCh  
423 challenge.

424        Following the lung function measurement, lungs were lavaged with 1.0 mL of saline two  
425        times, for a total of 2 mL containing 0.1 % ethylenediaminetetraacetic acid (EDTA; Sigma-  
426        Aldrich, St. Louis, MO). BALF was centrifuged to collect the immune cell pellet (1,000 xg, 10  
427        min, 4 °C) and the supernatant was collected and aliquoted prior to flash freezing in liquid  
428        nitrogen and storage at -80 °C. Immune cell pellet was resuspended in saline and the total  
429        immune cell count was estimated using a hemocytometer. For differential counts, cells were  
430        stained with a modified Wright-Giemsa stain (HEMA 3 STAT PACK, Fisher Scientific,  
431        Waltham, MA). Cell distribution was analyzed by manually identifying and counting  
432        eosinophils, neutrophils, macrophages and lymphocytes in six randomly chosen fields of view  
433        examined under a light microscope at 200 x magnification. Post-BAL lung tissue from the left  
434        lung and half the right lung were excised, portioned (~35 mg/each), wrapped in aluminum foil,  
435        placed in a 2.0 mL centrifuge tube prior to flash freezing in liquid nitrogen and storage at -80 °C  
436        until processed.

437

438        ***Assessment of protein extraction proficiency***

439        From each randomly chosen portion of frozen lung tissue (35 mg, wt/wt) our extraction  
440        process yielded an average of 1.146 mg of total protein. BALF yielding an average of 600 µg of  
441        total protein (100 µg per 250 µL aliquot) per mouse. Qualitative assessment of total protein  
442        molecular weight diversity was performed by gradient SDS-PAGE of both BALF and tissue  
443        protein lysates followed by coomassie blue staining. Using our extraction protocol, we obtained  
444        protein homogenates from both tissue (Supplemental 4A) and BALF (Supplemental 4B) rich in  
445        diverse molecular weight proteins. The dark band in BALF shown at ~66.5 kDa approximates  
446        the molecular weight of albumin as no high abundance protein depletion methods were  
447        employed for either BALF or tissue samples to reduce potential elimination bias.

448        To determine the quality of both technical and biological replicates we used mouse

449 BALF samples and performed two in parallel protein Filter Assisted Sample Preparation (FASP)  
450 procedures. We first examined our technical variation by assessing as early as possible the  
451 variation that might accumulate as we move identical samples through the FASP process. We  
452 divided the same sample into equal parts (100 µg total protein each) and processed the samples  
453 individually but in parallel through the entire FASP protocol and informatics pipeline. Our  
454 second experiment mirrored the first with exception to examining the effect that biological  
455 variation has on our FASP workflow. Our results show that technical variation (Supplemental  
456 4C,D) is lower than our biological variation (Supplemental 4E,F). Therefore, we negated the use  
457 of technical replicates for our proteomic analysis.

458

459 ***Preparation of lung tissue***

460 A randomly selected portioned lung tissue was thawed and weighed. The tissue surface  
461 was marred to increase surface area using scissors. To wash the lung tissue of residual blood  
462 contamination, each tissue sample was placed in a 15 mL centrifuge tube containing inhibitors  
463 dissolved in 15 mL PBS (-CaCl<sub>2</sub>, -MgCl<sub>2</sub>, pH 7.4; Invitrogen) and placed on an end-over-end  
464 mixer at 4 °C for 30 min. Inhibitors including Phenylmethylsulfonyl Fluoride (PMSF, 100 mM  
465 stock), Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich, St. Louis, MO), and Protease Inhibitor  
466 (Sigma-Aldrich) each at 1:100 dilution. Tissues were then removed and placed into siliconized  
467 2.0 mL centrifuge tubes (Thomas Scientific, Swedesboro, NJ) along with 100 µL of lysis buffer.  
468 Lysis buffer composition: 150 mM NaCl (Fisher Scientific), 50 mM Tris-HCL (pH 7.5; Fisher  
469 Scientific, Waltham, MA), 5 % glycerol (Sigma-Aldrich), 1 % sodium deoxycholate (Sigma-  
470 Aldrich), 1 % benzonase (25 U/µL; Merck, Kenilworth, NJ), 1 % sodium dodecyl sulfate (SDS;  
471 Fisher Scientific), Protease Inhibitor Cocktail 2 (1:100 dilution, Sigma-Aldrich), 1 mM PMSF  
472 (Sigma-Aldrich), Phosphatase Inhibitor Cocktail 2 (1:100 dilution, Sigma-Aldrich), 2 mM  
473 MgCl<sub>2</sub> (Fisher Scientific) built up with molecular grade water (Invitrogen). Tissue samples were

474      kept on ice during homogenization. Additional 100  $\mu$ L of homogenization buffer was added  
475      sequentially until an optimal ratio was obtained (400  $\mu$ L lysis buffer / 0.0335g lung tissue).  
476      Foaming was kept to a minimum by centrifugation throughout the homogenization process  
477      (10,000 xg, 30 s). Tissue homogenate was centrifuged (21,000 xg, 10 min, 4 °C, no break) and  
478      the supernatant was transferred to a separated siliconized centrifuge tube before incubating at  
479      room temperature for 30 min to permit benzonase activity before storing on ice. All chemicals  
480      used for tissue preparation were of molecular/electrophoresis grade. Tissues samples and  
481      homogenates were transferred and manipulated on wet ice (~4 °C) whenever possible.

482

483      ***Protein sample quality control***

484      BALF, samples were thawed on ice and spun (21,000 xg, 5 min, 4 °C, no break) and the  
485      pellets stored at -80 °C. The resulting supernatant was used for protein quantification using a  
486      micro bicinchoninic acid ( $\mu$ BCA) protein assay (Pierce, Waltham, MA) as per the  
487      manufacturer's instructions. Lung tissue homogenate was quantified using a DC-Lowery Kit  
488      (Bio-Rad DC Assay; Hercules, CA) as per the manufacturer's instructions. Both colourmetric  
489      kits were read using a UV-Vis spectrophotometer (BioTek; Winooski, VT) using quadrupole  
490      technical replicates. Homogenates were subsequently stored at -80 °C.

491      Identification of protein complexity by molecular weight for both BALF and tissue was  
492      discerned using SDS-PAGE and coomassie total protein stain. Briefly, (20  $\mu$ g total protein) was  
493      prepared in LDS-Loading buffer (Invitrogen) combined with 100 mM DTT (final conc.) and  
494      boiled for 5 min. After sample was cooled, proteins were loaded into a pre-cast Bis-Tris gradient  
495      gel (4-12 %, 1.0 mm, 10 well; NuPAGE; Invitrogen). With 20  $\mu$ g per tissue sample (7  $\mu$ g for  
496      BALF) and 5  $\mu$ L of protein standard (Page Ruler Plus, ThermoFisher Scientific, Cat no: 26619),  
497      samples were run at 75 V for 15 min before final separation at 150V until dye was run off the  
498      gel. Gels were washed to remove salt (MiliQ H<sub>2</sub>O, 50 rpm, 3 x 20 min wash) prior to coomassie

499 stain overnight (GelCode, Invitrogen) and destained for 1h (MiliQ H<sub>2</sub>O, 50 rpm, 3x20 min wash)  
500 to remove background before white field imaging (ChemiDock, Bio-Rad), (Supplemental Figure  
501 S4A,B).

502

503 ***Filter assisted sample preparation (FASP) of lung tissue***

504 We modified a previously used FASP protocol for use in lung tissue (Wisniewski *et al.*  
505 2009). Tissue homogenate (300 µg total protein) was supplemented with DTT (final  
506 concentration 100 mM) before boiling for 5 min, cooled and centrifuged (21,000 xg, 10 min, 4  
507 °C, no break) before transferring the supernatant to a siliconized centrifuge tube. Molecular  
508 weight cut off filters at 30 kDa (Amicron Ultra 0.5; Milipore; Burlington, MA) were tested for  
509 efficiency by adding 450 µL of 8 M urea (in 100 mM Tris in LCMS grade water) to each column  
510 and centrifuging them through (10,000 xg, 10 min, room temperature). Tissue homogenates were  
511 built with urea buffer (8 M urea, in LCMS grade 100 mM Tris) to 800 µL (to dilute SDS and  
512 deoxycholate in the sample) before loading onto tested 30 kDa molecular weight cut off columns  
513 (Milipore). Samples were repeatedly spun through the column (10,000 xg, 10 min, room  
514 temperature) until samples were fully loaded onto the column. Once samples were bound,  
515 columns were washed twice with urea buffer (450 µL) to wash out excess DTT (10,000 xg, 10  
516 min, room temperature). Samples were alkylated by adding 400 µL iodoacacidimide (IAA; 50 mM  
517 in urea buffer; Sigma-Aldrich) to the columns (45 mins, protected from light, room temperature).  
518 To halt the cysteine residue modifications by the IAA reaction, 20 mM DTT was added before  
519 centrifugation (13,000 xg, 10 min, room temperature). Columns were then washed twice with  
520 450 µL of urea buffer (13,000 xg, 10 min, room temperature) before one last hard spin to reduce  
521 the volume to a minimum within the column (14,000 xg, 15 min, room temperature). A fresh  
522 collection tube filled with 150 µL (98 % ACN, 2 % TFA) was then prepared used prior to  
523 trypsinization. Using a protein:trypsin ratio of 50:1 (Trypsin Gold; Promega; Madison, WI), 6 µg

524 of fresh trypsin (trypsin was dissolved in 1x digestion buffer; 50 mM Tris, 2 mM CaCl<sub>2</sub>, LCMS  
525 water) and filled to the top of the filter (~350 µL). Samples were sealed with parafilm and placed  
526 under shaking conditions at 37 °C for 16 h before the reaction was halted by the addition of TFA  
527 (1 % final concentration) and placing the samples at 4 °C. A saline solution (500 mM NaCl, final  
528 concentration) was added to each column prior to a test centrifugation (5,000 xg, 10 min, room  
529 temperature) to ensure filter integrity. Columns were then washed by adding 400 µL 50 %  
530 methanol (LCMS grade water), incubating for 5 min at room temperature prior to centrifugation  
531 (10,000 xg, 10 min, room temperature). A final wash was completed by adding 300 µL 15 %  
532 acetonitrile (LCMS grade water), incubating for 5 min at room temperature prior to  
533 centrifugation (10,000 xg, 10 min, room temperature). Flow through was transferred to a clean  
534 siliconized tube and a hard spin (13,000 xg, 10 min, room temperature) was then completed and  
535 merged with the remainder of the centrifuge tube. Samples were then frozen with the lids open at  
536 -80 °C until perfectly frozen to assist in sample drying by speed vac until dry (~4 h). Dried  
537 samples were sealed and frozen at -80 °C until ready for reconstitution.

538

539 ***Filter assisted sample preparation of BALF***

540 Mouse BALF samples were processed in a similar manner to that of mouse lung tissue  
541 with some minor changes to the protocol. Thawed BALF supernatant samples were centrifuged  
542 (10,000 xg, 5 min, 4 °C), 100 µg of total protein was denatured in 8M urea buffer with DTT (100  
543 mM final concentration) to a volume of 450 µL under mixing conditions for 1 h (room  
544 temperature) before loading onto 30 kDa molecular weight columns (Milipore) and proceeded to  
545 protein digestion steps mentioned previously.

546

547 ***Peptide desalting by reverse phase 1D-HPLC***

548 BALF or tissue lysate samples were warmed, inspected for condensation (if present put

549 on speed vac) and re-suspended in 800  $\mu$ L TFA (0.5 %, LCMS grade water), vortexed for 15 min  
550 until peptides dissolved, and centrifuged (21,000 xg, 10 min, 4 °C) to check for undissolved  
551 peptides before the supernatant was injected. BALF samples were loaded onto a C18 column  
552 (Luna 10  $\mu$ M C18(2), 100 Å, 50 x 4.6 mm; Phenomenex, Torrance, CA) while tissue lysate  
553 samples were loaded onto a separate C18 column (Phenomenex). Column efficiency and elution  
554 conditions were tested using a specialized 6 peptide solution prior to starting the samples  
555 (Krokhin and Spicer, 2009). Samples were collected at a flow rate of 500  $\mu$ L/min with an  
556 additional 30 s before and after the eluted peptide spectra was detected. Manual loading was used  
557 with no gradient. Agilent 1110 HPLC System using ChemStation for Control and Data Analysis  
558 (Santa Clara, CA) was used to analyze the chromatograms from Reverse Phase – HPLC (high  
559 pressure liquid chromatography). Samples were frozen at -80 °C with the lids open. All  
560 chemicals used were mass spec grade.

561

562 ***Reconstitution of sample & LC-MS/MS run***

563 Thawed samples were desiccated by speed vac (as previously mentioned) and  
564 reconstituted in 50  $\mu$ L formic acid (0.1 %, LCMS grade water). Samples were vortexed for 15  
565 min to encourage dissolving of the peptides. Peptide concentration was determined by UV  
566 spectrophotometry (Nanodrop Spectrophotometer 2000, ThermoFisher) at 280 nm.  
567 Spectrophotometer was checked for contamination between samples to ensure accurate  
568 measurements  $\pm$  10 nm. Peptides (2  $\mu$ g) were diluted in formic acid (0.1 %, LCMS grade water)  
569 and injected into the LC-MS/MS analysis at a flow rate of (500 nL/min). Samples were injected  
570 into an online LC-MS/MS workflow using a 3 h gradient run resulting in a 180 min run on a  
571 Sciex TripleTOF 5600 instrument (Sciex; Framingham, MA). Raw spectra files were converted  
572 into Mascot Generic File format (MGF) for protein identification using the tools bundled by the  
573 manufacturer. All chemicals used were mass spec grade.

574

575 ***Bioinformatic & statistical analysis***

576 The MGF files were processed by X!Tandem (Craig and Beavis, 2004) against single-  
577 missed-cleavage tryptic peptides from the *Mus musculus* Uniprot database (16704 proteins). The  
578 following X!Tandem search parameters were used: 20 ppm and 50 ppm mass tolerance for  
579 parent and fragment ions, respectively; constant modification of Cys with iodoacetamide; default  
580 set post-translational modifications: oxidation of Met, Trp; N-terminal cyclization at Qln, Cys;  
581 N-terminal acetylation, phosphorylation (Ser, Thr, Tyr), deamidation (Asn and Gln); an  
582 expectation value cut-off of  $\log_e < -1$  for both proteins and peptides.

583 Each MS run in yielded a list of protein expression values in a  $\log_2$  scale, quantified  
584 based on their member peptide MS2 fragment intensity sums. The simple rule of a quantified  
585 protein needing at least two non-redundant (unique) peptides with identification scores  $\log_e < -$   
586 1.5 each followed from our prior approaches. To correct for total protein loading differences  
587 when comparing between BALF and tissue, z-scores were calculated across the datasets. The  
588 Integrated-Tissue-BALF dataset is described as the combined proteomic profile of both the lung  
589 tissue and BALF datasets.

590 Partial least squares discriminant analysis (PLSDA) and its accompanied variable  
591 importance in projection (VIP) scores were calculated using the mixOmics package (v.6.3) in R  
592 using both z-scores and delineating 5 components for the discriminant analysis (Rohart *et al.*  
593 2017).

594 To separate proteins that are found only in either HDM or Naïve mice from those  
595 common to both, we plotted the z-scores from each dataset and assigned a z-score of -4 for any  
596 absent value. Statistical Analysis of Microarrays (SAM) was conducted using the SAMR (v2.0)  
597 package in R using only proteins common to both HDM & Naive groups across tissue and BALF  
598 and Integrated-Tissue-BALF datasets (Tusher *et al.* 2001). Delta values were selected based

599 upon an FDR  $\leq 10\%$  after 1,000 permutations. No  $\log_2$  correction or median centering was  
600 performed.

601 Univariate analysis was conducted using the LIMMA package (v3.3) in R (Ritchie *et al.*  
602 2015). Pathway Analysis was conducted using either InnateDB or Reactome with Benjamini-  
603 Hochberg multiple comparison adjustment (Breuer *et al.* 2013). For this analysis, Uniprot ID's  
604 alongside z-score fold changes (FC) were used from both the unique to treatment datasets and  
605 significantly identified proteins from SAM analysis. Missing values were assigned a value of -4  
606 prior to fold change calculation. Fold changes were calculated as the delta z-score (HDM-  
607 average Naïve).

608 Protein-protein interaction networks (first order with minimum connections) were  
609 identified using the InnateDB informatics source within NetworkAnalyst and accessed in July  
610 2019 (Breuer *et al.* 2013; Xia *et al.* 2014). The top 3 most interconnected protein hubs which are  
611 unique to either tissue or BALF were selected. Pathway analysis of these top hubs was  
612 determined through the open-source Reactome database using only Uniprot ID. Network  
613 enrichment analysis was limited to hubs in the Unique-to-Combined (UtC) dataset that have  $\geq 5$   
614 connections (Vallabhajosyula *et al.* 2009). The protein UBC was removed from all protein-  
615 protein interaction analysis.

616 All other visual tools were constructed using DataGraph (DataGraph v4.5, Visual Data  
617 Tools, Inc., Chapel Hill, NC, USA, <https://www.visualdatatools.com/>).

618 **Acknowledgements**

619 Work for this study was supported in part by the CIHR-Canadian Respiratory Research Network  
620 (CRRN), Research Manitoba and the DEVOTION Network, and the Biology of Breathing  
621 Group, Children's Hospital Research Institute of Manitoba. THM was supported by studentships  
622 from Research Manitoba, CRRN, AllerGen NCE Inc. and Asthma Canada. CDP was supported  
623 by a CIHR Banting Fellowship and a Research Manitoba Fellowship. AJ was supported by  
624 studentships from Research Manitoba and CRRN. AJH is supported through the Canada  
625 Research Chairs Program.

626

627 **Author Contributions**

628 THM performed all proteomics experiments, primary and secondary data analysis and prepared  
629 the manuscript draft. CDP provide supervision, guidance and assisted in the completed  
630 biostatistics and bioinformatics, design of figures, and editing and writing of the manuscript. AJ  
631 and SB were involved with experimental design and completion of animal studies. PE guided  
632 sample preparation and performed mass spectrometry. VS contributed to experimental design,  
633 primary proteomic data analysis, proteomic data quality control and primary statistics. NM  
634 contributed to experimental design and direction, and edited the manuscript. AJH conceived and  
635 led design of the study, including scope of biostatistics and bioinformatics, and contributed to  
636 writing and editing of the final manuscript.

637

638 **Conflict of Interest**

639 The authors declare no competing or financial interests.

## 640 References

641 Baarsma HA, Königshoff M, Gosens R (2013) The WNT signaling pathway from ligand  
642 secretion to gene transcription: molecular mechanisms and pharmacological targets. *Pharmacol*  
643 *Ther* 138: 66–83

644 Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, Winsor GL, Hancock RE,  
645 Brinkman FS, Lynn DJ (2013) InnateDB: systems biology of innate immunity and beyond--  
646 recent updates and continuing curation. *Nucleic Acids Res* 41: D1228–33

647 Burg D, Schofield JPR, Brandsma J, Staykova D, Folisi C, Bansal A, Nicholas B, Xian Y, Rowe  
648 A, Corfield J, Wilson S, Ward J, Lutter R, Fleming L, Shaw DE, Bakke PS, Caruso M, Dahlen  
649 SE, Fowler SJ, Hashimoto S, Horváth I, Howarth P, Krug N, Montuschi P, Sanak M, Sandström  
650 T, Singer F, Sun K, Pandis I, Auffray C, Sousa AR, Adcock IM, Chung KF, Sterk PJ,  
651 Djukanović R, Skipp PJ, The U-BSG (2018) Large-Scale Label-Free Quantitative Mapping of  
652 the Sputum Proteome. *J Proteome Res* 17: 2072–2091

653 Calderón MA, Linneberg A, Kleine-Tebbe J, De Blay F, Hernandez Fernandez de Rojas D,  
654 Virchow JC, Demoly P (2015) Respiratory allergy caused by house dust mites: What do we  
655 really know. *J Allergy Clin Immunol* 136: 38–48

656 Chan TK, Loh XY, Peh HY, Tan WNF, Tan WSD, Li N, Tay IJJ, Wong WSF, Engelward BP  
657 (2016) House dust mite-induced asthma causes oxidative damage and DNA double-strand breaks  
658 in the lungs. *J Allergy Clin Immunol* 138: 84–96.e1

659 Choopong J, Reamtong O, Sookrung N, Seesuay W, Indrawattana N, Sakolvaree Y, Chaicumpa  
660 W, Tungtrongchitr A (2016) Proteome, Allergenome, and Novel Allergens of House Dust Mite,  
661 Dermatophagoides farinae. *J Proteome Res* 15: 422–430

662 Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Théry  
663 C, Raposo G (2013) Analysis of ESCRT functions in exosome biogenesis, composition and  
664 secretion highlights the heterogeneity of extracellular vesicles. *J Cell Sci* 126: 5553–5565

665 Craig R, Beavis RC (2004) TANDEM: matching proteins with tandem mass spectra.

666 *Bioinformatics* 20: 1466–1467

667 Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes

668 cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* 102: 33–42

669 Halayko AJ, Amrani Y (2003) Mechanisms of inflammation-mediated airway smooth muscle

670 plasticity and airways remodeling in asthma. *Respir Physiol Neurobiol* 137: 209–222

671 Jha A, Ryu MH, Oo O, Bews HJ, Carlson JC, Schwartz J, Basu S, Wong CS, Halayko AJ (2018)

672 Prophylactic benefits of systemically delivered simvastatin treatment in a house dust mite

673 challenged murine model of allergic asthma. *Br J Pharmacol* 175: 1004–1016

674 Karim MA, Samyn DR, Mattie S, Brett CL (2018) Distinct features of multivesicular body-

675 lysosome fusion revealed by a new cell-free content-mixing assay. *Traffic* 19: 138–149

676 Koopmans T, Eilers R, Menzen M, Halayko A, Gosens R (2017)  $\beta$ -Catenin Directs Nuclear

677 Factor- $\kappa$ B p65 Output via CREB-Binding Protein/p300 in Human Airway Smooth Muscle. *Front*

678 *Immunol* 8: 1086

679 Krokhin OV, Spicer V (2009) Peptide retention standards and hydrophobicity indexes in

680 reversed-phase high-performance liquid chromatography of peptides. *Anal Chem* 81: 9522–9530

681 Kulshreshtha A, Ahmad T, Agrawal A, Ghosh B (2013) Proinflammatory role of epithelial cell-

682 derived exosomes in allergic airway inflammation. *J Allergy Clin Immunol* 131: 1194–203,

683 1203.e1

684 O’Neil SE, Sitkauskiene B, Babusyte A, Krisiukeniene A, Stravinskaite-Bieksiene K,

685 Sakalauskas R, Sihlbom C, Ekerljung L, Carlsohn E, Lötvall J (2011) Network analysis of

686 quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment. *Respir*

687 *Res* 12: 124

688 Petta I, Bougarne N, Vandewalle J, Dejager L, Vandevyver S, Ballegeer M, Desmet S, Thommis

689 J, De Cauwer L, Lievens S, Libert C, Tavernier J, De Bosscher K (2017) Glucocorticoid

690 Receptor-mediated transactivation is hampered by Striatin-3, a novel interaction partner of the  
691 receptor. *Sci Rep* 7: 8941

692 Piyadasa H, Altieri A, Basu S, Schwartz J, Halayko AJ, Mookherjee N (2016) Biosignature for  
693 airway inflammation in a house dust mite-challenged murine model of allergic asthma. *Biol  
694 Open* 5: 112–121

695 Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers  
696 differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res  
697* 43: e47

698 Rohart F, Gautier B, Singh A, Lê Cao KA (2017) mixOmics: An R package for ‘omics feature  
699 selection and multiple data integration. *PLoS Comput Biol* 13: e1005752

700 Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the  
701 ionizing radiation response. *Proc Natl Acad Sci U S A* 98: 5116–5121

702 Vallabhajosyula RR, Chakravarti D, Lufteali S, Ray A, Raval A (2009) Identifying hubs in  
703 protein interaction networks. *PLoS One* 4: e5344

704 Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method  
705 for proteome analysis. *Nat Methods* 6: 359–362

706 Wu J, Kobayashi M, Sousa EA, Liu W, Cai J, Goldman SJ, Dorner AJ, Projan SJ, Kavuru MS,  
707 Qiu Y, Thomassen MJ (2005) Differential proteomic analysis of bronchoalveolar lavage fluid in  
708 asthmatics following segmental antigen challenge. *Mol Cell Proteomics* 4: 1251–1264

709 Xia J, Benner MJ, Hancock RE (2014) NetworkAnalyst--integrative approaches for protein-  
710 protein interaction network analysis and visual exploration. *Nucleic Acids Res* 42: W167–74

711 **Tables**

712

713 **Table 1:** Proteins enriched in tissue, but diminished in the BALF proteome. Significantly  
714 enriched proteins (10) are highlighted in bold. Significance determined using a linear fit model in  
715 the R package LIMMA with Benjamini-Hochberg correction. Abbreviations used: log2 fold  
716 change (log<sub>2</sub>FC), adjusted p-value (p.adj), Uniprot identification number (Uniprot ID).

717

Uniprot	Gene	Description	log <sub>2</sub> FC	p-value	p.adj
P20065	Tmsb4x	Thymosin beta-4	4.536	9.23E-07	1.25E-05
Q62426	Cstb	Cystatin-B	4.031	9.25E-07	1.25E-05
Q99J08	Sec14l2	SEC14-like protein 2	5.029	8.29E-06	7.46E-05
P51855	Gss	Glutathione synthetase	3.784	1.47E-05	9.37E-05
Q2VLH6	Cd163	Scavenger receptor cysteine-rich type 1 protein M130	2.772	1.73E-05	9.37E-05
P70695	Fbp2	Fructose-1,6-bisphosphatase isozyme 2	3.593	1.03E-04	4.16E-04
P63254	Crip1	Cysteine-rich protein 1	1.419	1.08E-04	4.16E-04
Q9JHW2	Nit2	Omega-amidase NIT2	3.261	2.18E-04	7.34E-04
P15532	Nme1	Nucleoside diphosphate kinase A	1.029	5.68E-03	0.0171
P26883	Fkbp1a	Peptidyl-prolyl cis-trans isomerase FKBP1A	<b>0.659</b>	<b>1.81E-02</b>	<b>0.0488</b>
Q61646	Hp	Haptoglobin	0.806	3.50E-02	0.0818
Q9DBG5	Plin3	Perilipin-3	0.695	3.63E-02	0.0818
Q8VBW6	Nae1	NEDD8-activating enzyme E1 regulatory subunit	0.948	4.41E-02	0.0863
O35381	Anp32a	Acidic leucine-rich nuclear phosphoprotein 32 family member A	0.689	4.48E-02	0.0863
P35505	Fah	Fumarylacetoacetate	0.570	1.32E-01	0.2344
P17751	Tpi1	Triosephosphate isomerase	0.351	1.39E-01	0.2344
P10518	Alad	Delta-aminolevulinic acid dehydratase	0.352	1.58E-01	0.2431
P11352	Gpx1	Glutathione peroxidase 1	0.292	1.62E-01	0.2431
P13597	Icam1	Intercellular adhesion molecule 1	0.372	1.72E-01	0.2440
Q8K183	Pdkx	Pyridoxal kinase	0.499	1.92E-01	0.2591
Q9QYR9	Acot2	Acyl-coenzyme A thioesterase 2, mitochondrial	0.459	2.11E-01	0.2591
Q9CZ42	Carkd	ATP-dependent (S)-NAD(P)H-hydrate dehydratase	0.382	2.09E-01	0.2591
P05213	Tuba1b	Tubulin alpha-1B chain	0.743	2.31E-01	0.2594
P15626	Gstm2	Glutathione S-transferase Mu 2	0.421	2.30E-01	0.2594
P51125	Cast	Calpastatin	0.357	3.94E-01	0.4258
Q8BFZ3	Actbl2	Beta-actin-like protein 2	0.161	6.26E-01	0.6504
Q99J16	Rap1b	Ras-related protein Rap-1b	0.134	7.10E-01	0.7096

718

719 **Table 2:** Proteins enriched in BALF but diminished in the lung tissue proteome. Significantly  
 720 enriched proteins (141) are highlighted in bold. Significance determined using a linear fit model  
 721 in the R package LIMMA with Benjamini-Hochberg correction. Abbreviations used: log2 fold  
 722 change (log<sub>2</sub>FC), adjusted p-value (p.adj), Uniprot identification number (Uniprot ID).

Uniprot	Gene	Description	log <sub>2</sub> FC	p-value	p.adj
Q64475	Hist1h2bb	Histone H2B type 1-B	-7.500	1.00E-09	2.00E-07
P48678	Lmna	Prelamin-A/C	-4.004	5.72E-08	3.82E-06
P62715	Ppp2cb	Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform	-4.003	5.46E-08	3.82E-06
<b>P15508</b>	<b>Sptb</b>	Spectrin beta chain, erythrocytic	-4.851	<b>8.00E-08</b>	<b>4.00E-06</b>
P31725	S100a9	Protein S100-A9	-4.486	1.36E-07	4.25E-06
P15864	<b>Hist1h1c</b>	<b>Histone H1.2</b>	-4.333	1.53E-07	4.25E-06
Q3THE2	<b>Myl12b</b>	<b>Myosin regulatory light chain 12B</b>	-4.228	1.58E-07	4.25E-06
Q8VCW8	Acsf2	Acyl-CoA synthetase family member 2, mitochondrial	-4.052	1.86E-07	4.25E-06
P46638	Rab11b	Ras-related protein Rab-11B	-3.623	1.91E-07	4.25E-06
Q8C1B7	Sept11	Septin-11	-3.926	2.88E-07	5.75E-06
Q8CIB5	Fermt2	Fermitin family homolog 2	-3.941	3.54E-07	6.44E-06
Q61879	Myh10	Myosin-10	-4.212	5.80E-07	9.19E-06
Q8BT60	Cpne3	Copine-3	-4.166	7.19E-07	9.19E-06
Q9WVK4	Ehd1	EH domain-containing protein 1	-3.722	7.32E-07	9.19E-06
P16546	Sptan1	Spectrin alpha chain, non-erythrocytic 1	-3.700	6.37E-07	9.19E-06
Q9EPC1	Parva	Alpha-parvin	-3.486	7.35E-07	9.19E-06
Q99NB1	Acss1	Acetyl-coenzyme A synthetase 2-like, mitochondrial	-3.850	1.08E-06	1.14E-05
P68368	Tuba4a	Tubulin alpha-4A chain	-3.774	1.03E-06	1.14E-05
Q8BHZ0	Fam49a	Protein FAM49A	-2.793	1.02E-06	1.14E-05
Q8K1B8	Fermt3	Fermitin family homolog 3	-3.831	1.19E-06	1.19E-05
O35215	Ddt	D-dopachrome decarboxylase	-4.226	1.37E-06	1.24E-05
P35282	Rab21	Ras-related protein Rab-21	-3.751	1.43E-06	1.24E-05
Q62261	Sptbn1	Spectrin beta chain, non-erythrocytic 1	-3.636	1.40E-06	1.24E-05
P68369	Tuba1a	Tubulin alpha-1A chain	-5.702	1.62E-06	1.29E-05
Q91ZX7	Lrp1	Prolow-density lipoprotein receptor-related protein 1	-3.775	1.67E-06	1.29E-05
Q91YR1	Twf1	Twinfilin-1	-3.641	1.68E-06	1.29E-05
P54071	Idh2	Isocitrate dehydrogenase [NADP], mitochondrial	-3.655	1.84E-06	1.36E-05
Q8CGB6	Tenc1	Tensin-like C1 domain-containing phosphatase	-3.972	1.98E-06	1.36E-05
P12382	Pfk1	ATP-dependent 6-phosphofructokinase, liver type	-3.954	1.95E-06	1.36E-05
Q61425	Hadh	Hydroxylacyl-coenzyme A dehydrogenase, mitochondrial	-3.781	2.09E-06	1.39E-05
Q8BFW7	Lpp	Lipoma-preferred partner homolog	-3.680	2.37E-06	1.48E-05
Q9CZ44	Nsfl1c	NSFL1 cofactor p47	-3.515	2.37E-06	1.48E-05
P10630	Eif4a2	Eukaryotic initiation factor 4A-II	-4.160	2.48E-06	1.50E-05
Q8VI36	Pxn	Paxillin	-3.701	3.11E-06	1.83E-05
P08752	Gnai2	Guanine nucleotide-binding protein G(i) subunit alpha-2	-3.762	3.23E-06	1.85E-05
Q7TSV4	Pgm2	Phosphoglucomutase-2	-3.709	3.56E-06	1.92E-05
P48722	Hspa4l	Heat shock 70 kDa protein 4L	-3.701	3.55E-06	1.92E-05
Q62465	Vat1	Synaptic vesicle membrane protein VAT-1 homolog	-3.820	4.02E-06	2.01E-05
O35955	Psmb10	Proteasome subunit beta type-10	-3.786	3.84E-06	2.01E-05
Q9WUB3	Pygm	Glycogen phosphorylase, muscle form	-3.655	3.99E-06	2.01E-05
P70372	Elavl1	ELAV-like protein 1	-3.904	4.33E-06	2.04E-05
Q9CS42	Prps2	Ribose-phosphate pyrophosphokinase 2	-3.355	4.31E-06	2.04E-05
Q62348	Tsn	Translin	-2.753	4.38E-06	2.04E-05
Q9JJ28	Flii	Protein flightless-1 homolog	-3.753	4.49E-06	2.04E-05
Q8VE70	Pdcd10	Programmed cell death protein 10	-3.831	4.84E-06	2.15E-05
Q8QZT1	Acat1	Acetyl-CoA acetyltransferase, mitochondrial	-3.760	5.84E-06	2.54E-05
Q64331	Myo6	Unconventional myosin-VI	-4.237	6.00E-06	2.54E-05
Q8VIJ6	Sfpq	Splicing factor, proline- and glutamine-rich	-3.654	6.10E-06	2.54E-05
Q8VE97	Srsf4	Serine/arginine-rich splicing factor 4	-3.882	6.25E-06	2.55E-05
Q9WTI7	Myo1c	Unconventional myosin-Ic	-3.517	6.72E-06	2.69E-05
Q8C3J5	Dock2	Dedicator of cytokinesis protein 2	-4.074	8.04E-06	3.03E-05
Q3TCJ1	Fam175b	BRISC complex subunit Abro1	-3.722	7.95E-06	3.03E-05
Q99020	Hnrnpab	Heterogeneous nuclear ribonucleoprotein A/B	-3.650	7.88E-06	3.03E-05
P32067	Ssb	Lupus La protein homolog	-3.664	8.79E-06	3.15E-05
Q9QXZ0	Macf1	Microtubule-actin cross-linking factor 1	-3.656	8.81E-06	3.15E-05
O55234	Psmb5	Proteasome subunit beta type-5	-2.439	8.52E-06	3.15E-05
Q9ZOU1	Tjp2	Tight junction protein ZO-2	-3.737	9.36E-06	3.23E-05
Q9ET54	Palld	Palladin	-3.689	9.44E-06	3.23E-05
Q8BH95	Echs1	Enoyl-CoA hydratase, mitochondrial	-3.642	9.69E-06	3.23E-05
Q8BK64	Ahsa1	Activator of 90 kDa heat shock protein ATPase homolog 1	-3.284	9.57E-06	3.23E-05
Q8BFY9	Tnpo1	Transportin-1	-3.695	1.02E-05	3.34E-05
Q6P1F6	Ppp2r2a	Serine/threonine-protein phosphatase 2A 55 kDa regulatory	-3.396	1.05E-05	3.40E-05

Q9JHU4	Dync1h1	subunit B alpha isoform			
P84084	Arf5	Cytoplasmic dynein 1 heavy chain 1	-3.791	1.18E-05	3.74E-05
P26231	Ctnna1	ADP-ribosylation factor 5	-3.657	1.29E-05	4.03E-05
P33267	Cyp2f2	Catenin alpha-1	-3.328	1.35E-05	4.15E-05
P35278	Rab5c	Cytochrome P450 2F2	-4.277	1.40E-05	4.23E-05
Q01730	Rsu1	Ras-related protein Rab-5C	-3.161	1.87E-05	5.57E-05
Q9DBR7	Ppp1r12a	Ras suppressor protein 1	-3.466	2.06E-05	6.05E-05
Q9WTQ5	Akap12	Protein phosphatase 1 regulatory subunit 12A	-3.784	2.32E-05	6.71E-05
P28660	Nckap1	A-kinase anchor protein 12	-3.878	2.51E-05	7.14E-05
O35737	Hnrnph1	Nck-associated protein 1	-3.545	2.53E-05	7.14E-05
Q9D8T2	Gsdmdc1	Heterogeneous nuclear ribonucleoprotein H	-4.026	2.66E-05	7.38E-05
Q62219	Tgfb1i1	Gasdermin-D	-2.587	3.34E-05	9.16E-05
Q9Z0P5	Twf2	Transforming growth factor beta-1-induced transcript 1 protein	-3.833	3.45E-05	9.29E-05
Q64514	Tpp2	Twinfilin-2	-3.217	3.49E-05	9.29E-05
Q9D358	Acp1	Tripeptidyl-peptidase 2	-3.674	3.99E-05	1.05E-04
Q99L45	Eif2s2	Low molecular weight phosphotyrosine protein phosphatase	-3.384	4.13E-05	1.07E-04
O88544	Cops4	Eukaryotic translation initiation factor 2 subunit 2	-3.200	4.34E-05	1.11E-04
Q60994	Adipoq	COP9 signalosome complex subunit 4	-3.369	4.82E-05	1.22E-04
Q6URW6	Myh14	Adiponectin	-2.786	5.36E-05	1.34E-04
Q9R1T2	Sae1	Myosin-14	-3.386	5.60E-05	1.38E-04
Q9QXS1	Plec	SUMO-activating enzyme subunit 1	-3.455	5.73E-05	1.40E-04
Q8BH61	F13a1	Plectin	-3.131	5.92E-05	1.43E-04
Q8BYA0	Tbcd	Coagulation factor XIII A chain	-2.444	6.01E-05	1.43E-04
Q9JLV1	Bag3	Tubulin-specific chaperone D	-2.024	8.51E-05	2.00E-04
Q61838	A2m	BAG family molecular chaperone regulator 3	-3.280	8.97E-05	2.09E-04
P35123	Usp4	Alpha-2-macroglobulin	-1.743	1.08E-04	2.49E-04
P26043	Rdx	Ubiquitin carboxyl-terminal hydrolase 4	-2.167	1.10E-04	2.49E-04
Q9CQD1	Rab5a	Radixin	-1.453	1.11E-04	2.49E-04
Q3UDE2	Ttl12	Ras-related protein Rab-5A	-3.723	1.13E-04	2.51E-04
Q9JM14	Nt5c	Tubulin--tyrosine ligase-like protein 12	-2.927	1.19E-04	2.61E-04
Q61151	Ppp2r5e	5'(3')-deoxyribonucleotidase, cytosolic type	-1.335	1.21E-04	2.62E-04
		Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform	-2.475	1.29E-04	2.78E-04
P28665	Mug1	Murinoglobulin-1	-1.768	1.74E-04	3.70E-04
P70335	Rock1	Rho-associated protein kinase 1	-3.247	1.82E-04	3.83E-04
Q99JI1	Mustn1	Musculoskeletal embryonic nuclear protein 1	-2.387	1.98E-04	4.14E-04
Q00623	Apoa1	Apolipoprotein A-I	-1.449	2.16E-04	4.45E-04
E9PV24	Fga	Fibrinogen alpha chain	-1.722	2.48E-04	5.07E-04
P07309	Ttr	Transthyretin	-1.336	3.49E-04	7.05E-04
Q8BGD9	Eif4b	Eukaryotic translation initiation factor 4B	-3.433	3.56E-04	7.11E-04
Q80TM9	Nisch	Nischarin	-2.752	4.07E-04	8.05E-04
Q8VCM7	Fgg	Fibrinogen gamma chain	-1.256	4.18E-04	8.19E-04
Q99JW4	Lims1	LIM and senescent cell antigen-like-containing domain protein 1	-1.242	6.39E-04	0.0012
O88456	Capns1	Calpain small subunit 1	-1.277	6.92E-04	0.0013
Q6P069	Sri	Sorcin	-1.454	7.38E-04	0.0014
P08249	Mdh2	Malate dehydrogenase, mitochondrial	-1.168	7.87E-04	0.0015
P00329	Adh1	Alcohol dehydrogenase 1	-1.144	1.43E-03	0.0027
P32261	Serpinc1	Antithrombin-III	-1.208	1.48E-03	0.0027
A2ASS6	Ttn	Titin	-1.049	1.52E-03	0.0028
Q07076	Anxa7	Annexin A7	-1.162	2.02E-03	0.0037
P26039	Tln1	Talin-1	-0.981	2.06E-03	0.0037
Q3UH68	Limch1	LIM and calponin homology domains-containing protein 1	-1.402	2.20E-03	0.0039
P63087	Ppp1cc	Serine/threonine-protein phosphatase PP1-gamma catalytic subunit	-0.984	2.43E-03	0.0043
Q8K0E8	Fgb	Fibrinogen beta chain	-1.311	2.48E-03	0.0043
Q9DC07	Neb1	LIM zinc-binding domain-containing Nebulette	-1.119	2.74E-03	0.0048
P52430	Pon1	Serum paraoxonase/arylesterase 1	-0.878	3.32E-03	0.0057
P97333	Nrp1	Neuropilin-1	-1.362	3.67E-03	0.0063
P48036	Anxa5	Annexin A5	-0.806	4.08E-03	0.0069
Q08879	Fbln1	Fibulin-1	-1.766	4.27E-03	0.0072
Q9WV60	Gsk3b	Glycogen synthase kinase-3 beta	-2.109	5.17E-03	0.0086
Q9EPK7	Xpo7	Exportin-7	-1.200	5.30E-03	0.0088
P58871	Tnks1bp1	182 kDa tankyrase-1-binding protein	-1.284	5.44E-03	0.0089
P47738	Aldh2	Aldehyde dehydrogenase, mitochondrial	-1.011	5.78E-03	0.0094
Q92111	Tf	Serotransferrin	-0.806	6.48E-03	0.0105
Q91VC7	Ppp1r14a	Protein phosphatase 1 regulatory subunit 14A	-1.136	7.74E-03	0.0124
P24270	Cat	Catalase	-0.675	7.80E-03	0.0124
P97447	Fhl1	Four and a half LIM domains protein 1	-0.678	9.59E-03	0.0151
P40936	Inmt	Indolethylamine N-methyltransferase	-0.793	1.04E-02	0.0163
P68033	Actc1	Actin, alpha cardiac muscle 1	-2.423	1.09E-02	0.0168
P62204	Calm1	Calmodulin	-0.785	1.08E-02	0.0168
Q91X72	Hpx	Hemopexin	-0.684	1.22E-02	0.0187
P51174	Acadl	Long-chain specific acyl-CoA dehydrogenase, mitochondrial	-0.696	1.24E-02	0.0189
Q61RU2	Tpm4	Tropomyosin alpha-4 chain	-0.737	1.30E-02	0.0195
P60766	Cdc42	Cell division control protein 42 homolog	-0.715	1.34E-02	0.0199
Q9CZY3	Ube2v1	Ubiquitin-conjugating enzyme E2 variant 1	-0.693	1.33E-02	0.0199

P97315	Csrp1	Cysteine and glycine-rich protein 1	-0.731	1.67E-02	0.0245
Q6A028	Swap70	Switch-associated protein 70	-0.790	1.93E-02	0.0282
P63260	Actg1	Actin, cytoplasmic 2	-3.539	2.26E-02	0.0328
P08226	Apoe	Apolipoprotein E	-0.528	2.82E-02	0.0406
Q08857	Cd36	Platelet glycoprotein 4	-0.732	3.06E-02	0.0437
Q01339	Apoh	Beta-2-glycoprotein 1	-0.654	3.08E-02	0.0437
Q9WVH9	Fbln5	Fibulin-5	-0.667	3.76E-02	0.0530
Q64471	Gstt1	Glutathione S-transferase theta-1	-0.683	3.85E-02	0.0538
O55222	Ilk	Integrin-linked protein kinase	-0.773	3.93E-02	0.0545
Q9JJU8	Sh3bgrl	SH3 domain-binding glutamic acid-rich-like protein	-0.610	4.39E-02	0.0606
Q61147	Cp	Ceruloplasmin	-0.496	4.79E-02	0.0657
Q9CPU0	Glo1	Lactoylglutathione lyase	-0.487	5.45E-02	0.0741
Q06890	Clu	Clusterin	-0.452	5.73E-02	0.0774
O55135	Eif6	Eukaryotic translation initiation factor 6	-0.614	6.25E-02	0.0838
P14602	Hspb1	Heat shock protein beta-1	-0.721	6.92E-02	0.0923
P51885	Lum	Lumican	-0.475	7.10E-02	0.0941
Q9JLJ2	Aldh9a1	4-trimethylaminobutyraldehyde dehydrogenase	-0.719	7.18E-02	0.0945
P35235	Ptpn11	Tyrosine-protein phosphatase non-receptor type 11	0.374	8.48E-02	0.1109
Q6PDN3	Mylk	Myosin light chain kinase, smooth muscle	-0.702	9.13E-02	0.1186
P34884	Mif	Macrophage migration inhibitory factor	-0.414	9.40E-02	0.1212
Q61171	Prdx2	Peroxiredoxin-2	-0.532	9.77E-02	0.1253
P00920	Ca2	Carbonic anhydrase 2	-0.467	9.90E-02	0.1261
O35639	Anxa3	Annexin A3	-0.382	9.99E-02	0.1264
P68510	Ywhah	14-3-3 protein eta	-0.351	1.03E-01	0.1292
P01942	Hba	Hemoglobin subunit alpha	-0.713	1.04E-01	0.1304
Q9D0J8	Ptms	Parathymosin	-0.406	1.06E-01	0.1317
P62806	Hist1h4a	Histone H4	-0.582	1.16E-01	0.1433
P70202	Lxn	Latexin	-0.458	1.17E-01	0.1433
Q8BPB5	Efemp1	EGF-containing fibulin-like extracellular matrix protein 1	-0.495	1.22E-01	0.1492
Q64727	Vcl	Vinculin	-0.376	1.24E-01	0.1509
Q9DC11	Plxdc2	Plexin domain-containing protein 2	0.394	1.54E-01	0.1858
Q62000	Ogn	Mimecan	-0.660	1.59E-01	0.1895
P24549	Aldh1a1	Retinal dehydrogenase 1	-0.431	1.59E-01	0.1895
P27546	Map4	Microtubule-associated protein 4	-0.355	1.67E-01	0.1976
P60710	Actb	Actin, cytoplasmic 1	-0.836	1.76E-01	0.2075
P23953	Ces1c	Carboxylesterase 1C	-0.405	1.83E-01	0.2136
P02089	Hbb-b2	Hemoglobin subunit beta-2	-0.580	1.99E-01	0.2300
Q8CG76	Akr7a2	Aflatoxin B1 aldehyde reductase member 2	-0.392	1.98E-01	0.2300
Q99KJ8	Dctn2	Dynactin subunit 2	-0.367	2.10E-01	0.2410
O09164	Sod3	Extracellular superoxide dismutase [Cu-Zn]	-0.275	2.12E-01	0.2419
P17563	Selenbp1	Selenium-binding protein 1	-0.260	2.38E-01	0.2708
P14152	Mdh1	Malate dehydrogenase, cytoplasmic	-0.270	2.41E-01	0.2716
P63330	Ppp2ca	Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform	-0.266	2.42E-01	0.2716
O08677	Kng1	Kininogen-1	-0.432	2.46E-01	0.2735
P13020	Gsn	Gelsolin	-0.283	2.46E-01	0.2735
Q99K51	Pls3	Plastin-3	-0.228	2.66E-01	0.2941
P08228	Sod1	Superoxide dismutase [Cu-Zn]	-0.239	2.83E-01	0.3109
Q9WVA4	Tagln2	Transgelin-2	-0.226	2.95E-01	0.3221
P02088	Hbb-b1	Hemoglobin subunit beta-1	-0.477	3.16E-01	0.3434
Q60854	Serpina6	Serpin B6	-0.214	3.24E-01	0.3502
P50396	Gdi1	Rab GDP dissociation inhibitor alpha	-0.202	3.26E-01	0.3506
P22599	Serpina1b	Alpha-1-antitrypsin 1-2	-0.266	3.93E-01	0.4205
Q99K30	Eps8l2	Epidermal growth factor receptor kinase substrate 8-like protein 2	-0.401	4.06E-01	0.4317
P30416	Fkbp4	Peptidyl-prolyl cis-trans isomerase FKBP4	-0.421	4.09E-01	0.4325
O08709	Prdx6	Peroxiredoxin-6	-0.163	4.32E-01	0.4551
Q06770	Serpina6	Corticosteroid-binding globulin	-0.377	4.41E-01	0.4619
O08553	Dpysl2	Dihydropyrimidinase-related protein 2	-0.144	5.03E-01	0.5240
Q9DBF1	Aldh7a1	Alpha-aminoacidic semialdehyde dehydrogenase	-0.117	5.63E-01	0.5834
P58389	Ppp2r4	Serine/threonine-protein phosphatase 2A activator	-0.138	5.67E-01	0.5849
P19221	F2	Prothrombin	-0.209	6.14E-01	0.6294
P49443	Ppm1a	Protein phosphatase 1A	-0.237	6.26E-01	0.6388
P63101	Ywhaz	14-3-3 protein zeta/delta	-0.099	6.68E-01	0.6785
Q8BH64	Ehd2	EH domain-containing protein 2	-0.144	6.72E-01	0.6785
P06728	Apoa4	Apolipoprotein A-IV	-0.085	7.44E-01	0.7477
P20918	Plg	Plasminogen	-0.053	8.79E-01	0.8790

724 **Figure Legends**

725 **Figure 1:** Characterization of the distinct proteomic signatures of the lung tissue and BALF. **A)**  
726 Venn Diagram showing distribution of unique protein ID's for the lung tissue and BALF across  
727 both naïve and HDM exposed mice. **B)** PLSDA of the proteomes from the tissue, BALF and  
728 Integrated-Tissue-BALF datasets as influenced by HDM treatment. **C)** Variance in Projection  
729 (VIP) score for the PLSDA shown in B identifies the top proteins that discriminate the  
730 proteomes of the tissue, BALF and Integrated-Tissue-BALF proteomes. Z-scores are shown on  
731 the right-hand side to show individual contributions from each proteomic dataset. Abbreviations  
732 used: Partial Least Squares Discriminant Analysis (PLSDA), House Dust Mite (HDM), BALF  
733 (B), tissue (T), Integrated-Tissue-BALF (I).

734 **Figure 2:** Differential expression analysis identifies both unique and significantly enriched  
735 proteins from tissue, BALF and Integrated-Tissue-BALF proteomes during HDM challenge. **A,**  
736 **B, C)** Insets: z-score plots from HDM treated and naïve mice. Proteins exclusive to either HDM  
737 or naïve samples are represented by assigning a z-score of -4 to the missing values. Proteins  
738 found in both HDM and naïve mice were used for SAM analysis and represented as volcano  
739 plots. Significance was taken at  $p \leq 0.05$  after False Discovery Rate (FDR) correction. Proteins  
740 unique to the tissue or BALF proteomes are coloured red and blue respectively (A,B). Proteins  
741 unique to lung tissue or BALF proteomes when examined in isolation are colored in green (C).  
742 **D)** Proteins that are found in both lung tissue and BALF but are differentially enriched. **E-F)**  
743 Pathway analysis (top 10) using significantly enriched lung tissue proteins (diminished in BALF;  
744 E) and proteins that are enriched in BALF (diminished in tissue; F). Pathway analysis was  
745 conducted using InnateDB with an adjusted p-value by Benjamini-Hochberg multiple  
746 comparison. Vertical lines (E,F) indicate statistical significance ( $p.\text{adj } p = 0.05$ ).

747 **Figure 3:** Individually, lung tissue or BALF proteomes do not recapitulate the biology of the  
748 Integrated-Tissue-BALF proteome. **A, B)** Significantly enriched pathways activated by HDM  
749 exposure for the lung tissue (A), and BALF proteomes (B). **C)** Pathways that are enriched in the  
750 tissue and the Integrated-Tissue-BALF proteome ( $p.\text{adj} \leq 0.05$ ) but not the BALF proteome  
751 ( $p.\text{adj} > 0.05$ ). **D)** Pathways that are enriched in the BALF and the Integrated-Tissue-BALF  
752 proteome ( $p.\text{adj} \leq 0.05$ ) but not the lung tissue ( $p.\text{adj} > 0.05$ ). **E)** Pathways that are enriched in  
753 the Integrated-Tissue-BALF proteome ( $p.\text{adj} \leq 0.05$ ) but are not enriched in either the lung tissue  
754 or BALF proteomes ( $p.\text{adj} > 0.05$ ). Pathway analysis was conducted using InnateDB using  
755 Uniprot Protein IDs. Vertical black line indicates significance ( $p.\text{adj} \leq 0.05$ ) after Benjamini-  
756 Hochberg multiple comparison correction.

757 **Figure 4:** Protein-Protein interaction networks that drive the lung tissue, BALF and Integrated-  
758 Tissue-BALF proteome biology are distinct. **A)** Top 3 most connected protein hubs (protein-  
759 protein interactions) that are unique to the lung tissue dataset (Hdac1, Ctnnb1, Smarca4). **B)** Top  
760 3 most connected protein hubs that are unique to the BALF dataset (Csf1r, Dnm1, Akt1). **C)** The  
761 Integrated-Tissue-BALF protein-protein interaction network using the top 3 hubs identified from  
762 either the lung tissue or BALF datasets (Hdac1, Ctnnb1, Smarca4, Csf1r, Dnm1, Akt1). The  
763 most significantly enriched biological associations ( $p.\text{adj} \leq 0.05$ ) determined using the Reactome  
764 module of NetworkAnalyst for each interactome is shown on the right-hand side of panel. Hubs  
765 are coloured to identify direct protein-protein interactions.

766

767 **Figure 5:** Integrating proteomes not only enrich protein-protein interactions but also connects  
768 otherwise separate proteomes together. **(A)** Interactome map based on proteins that are unique to  
769 tissue **(B)** Interactome map based on proteins that are unique to BALF. **(C)** Interactome map on  
770 unique to-lung tissue and -BALF protein hubs in the UtC dataset. The most significantly  
771 enriched biological associations ( $p.\text{adj} \leq 0.05$ ) determined using the Reactome module of  
772 NetworkAnalyst for each interactome is shown on the right hand side of panel. Hubs are  
773 coloured to identify direct protein-protein interactions. Black lines signify interactions between  
774 different protein hubs. Proteins which have split colouration are connected to two independent  
775 protein hubs.

776 **Table 3A:** Lung tissue protein hub enrichment in the Unique-to Combined dataset. We identified  
777 the protein interaction hubs that are unique to lung tissue and become enriched in the Unique-to-  
778 Combined dataset. For simplicity, the Unique-to-Combined dataset was filtered to have  $\geq 5$   
779 connections and only the top 10 protein hubs (by % enrichment) are shown. Proteins in bold  
780 were selected for further analysis.

Unique to	Uniprot ID	Gene	# of Interactions		Protein Hub Enrichment in the Unique-to-Combined Dataset (%)
			Tissue	Unique-to-Combined	
Tissue	<b>Q99LI8</b>	<b>Hgs</b>	<b>6</b>	<b>8</b>	<b>33.33</b>
Tissue	<b>Q9ES28</b>	<b>Arhgef7</b>	<b>8</b>	<b>10</b>	<b>25.00</b>
Tissue	<b>Q9DBR0</b>	<b>Akap8</b>	<b>4</b>	<b>5</b>	<b>25.00</b>
Tissue	Q9CQU3	Rer1	5	6	20.00
Tissue	Q9Z2N8	Actl6a	5	6	20.00
Tissue	Q80TH2	Erbb2ip	6	7	16.67
Tissue	P09242	Alpl	6	7	16.67
Tissue	Q9Z277	Baz1b	6	7	16.67
Tissue	P70452	Stx4a	6	7	16.67
Tissue	Q68FF6	Git1	7	8	14.29

781

782

783 **Table 3B:** BALF Protein hub enrichment in the Unique-to-Combined dataset. We identified the  
784 protein interaction hubs that are unique to BALF and become enriched in the Unique-to-  
785 Combined dataset. For simplicity, the Unique-to-Combined dataset was filtered to have  $\geq 5$   
786 connections and only the top 10 protein hubs (by % enrichment) are shown. Proteins in bold  
787 were selected for further analysis.

Unique to	Uniprot ID	Gene	# of Interactions		Protein Hub Enrichment in the Unique-to-Combined Dataset (%)
			BALF	Unique-to-Combined	
BALF	<b>P97864</b>	<b>Casp7</b>	<b>7</b>	<b>13</b>	<b>85.71</b>
BALF	<b>P83940</b>	<b>Tceb1</b>	<b>3</b>	<b>5</b>	<b>66.67</b>
BALF	<b>P10923</b>	<b>Spp1</b>	<b>4</b>	<b>6</b>	<b>50.00</b>
BALF	<b>P39053</b>	<b>Dnm1</b>	<b>14</b>	<b>21</b>	<b>50.00</b>
BALF	O70456	Sfn	5	7	40.00
BALF	P31750	Akt1	14	19	35.71
BALF	Q01279	Egfr	13	17	30.77
BALF	P33175	Kif5a	8	10	25.00
BALF	P97797	Sirpa	8	10	25.00
BALF	P68134	Acta1	8	9	12.50

788

789

790 **Supplementary Information (Expanded View)**

791

792 **Supplemental 1:** Experimental Workflow. Six mice were split into two groups and exposed to  
793 either HDM (House Dust Mite) or PBS (naïve) for two weeks. On day 14, mice were  
794 anesthetized and lung function data was collected using a small animal ventilator. Bronchial  
795 Alveolar Lavage Fluid (BALF) was collected, spun down to collect immune cells and flash  
796 frozen in liquid nitrogen. Post-BAL lung tissue was portioned into 5 equal segments and flash  
797 frozen in liquid nitrogen. Lung tissue was washed in PBS to remove excess blood and  
798 subsequently homogenized. Samples were processed using FASP (Filter Assisted Sample  
799 Preparation), trypsinized, desalted by 1D HPLC and quantified using an online LC-MS/MS  
800 proteomic system. Protein ID's were identified using our X!Tandem informatic pipeline and  
801 subsequent bioinformatic analysis was conducted on the data. On a per sample basis, log2  
802 normalized protein abundance was converted to z-scores and then normalized to HDM exposure.  
803 Using these normalized datasets, the Tissue, BALF and the Integrated-Tissue-BALF and  
804 Unique-to-Combined datasets were used as inputs to assess the differences between the BALF  
805 and tissue datasets across multiple levels of analysis including proteins, pathways and networks.

806 **Supplemental 2:** HDM exposure induces altered lung function and increased inflammatory cell  
807 counts. **A)** Lung mechanics were measured 48 h after last HDM treatment using a flexivent small  
808 animal ventilator. Increasing doses of methacholine (3-50 mg/mL) intranasally administered to  
809 measure changes in airway resistance, tissue resistance and tissue elastance. **B)** Differential  
810 immune cell counts from Bronchial Alveolar Lavage Fluid (BALF) of naïve and HDM exposed  
811 mice. Each value is representative of the mean and SEM of three biological replicates. Statistical  
812 significance was determined by a two-way nested ANOVA with Tukey's post-hoc test for lung  
813 function and unpaired t-test with welch's correction for cell counts. FDR corrected p-values are  
814 reported. \*(p.adj ≤ 0.05), \*\*(p.adj ≤ 0.01), \*\*\*\*(p.adj ≤ 0.0001).

815 **Supplemental 3:** Summary of MS/MS analysis from X!Tandem informatic pipeline.

816 **A)** Distribution of spectra, non-redundant peptides and quantified protein IDs are significantly

817 enriched in tissue compared to BALF samples. An EV cutoff of -1.5 and a minimum of two

818 peptides were needed for each peptide and protein ID. **B)** Summary of MS/MS data. Unpaired

819 one-way t-test with welch's correction and FDR adjustment was used for statistical analysis.

820 Abbreviations used: Mouse (In House Mouse ID), number of spectra (SPEC), number of

821 peptides (PEPS), number of non-pedundant peptides (NR-PEPS), number of proteins (PROTS),

822 number of quantified proteins (QPROT), number of quantified peptides (QPEPS), Mean and

823 Standard Deviation of Log<sub>2</sub> MS/MS Intensity (MEAN & SD), Bronchial Alveolar Lavage Fluid

824 (BALF), House Dust Mite (HDM). \*(p.adj ≤ 0.05), \*\*\*\*(p.adj ≤ 0.0001).

825 **Supplemental 4:** Proteomic quality control and reproducibility tests indicate proteomic  
826 variability resides in biological and not technical replicates. **A,B)** Representative SDS-PAGE  
827 gels stained for total protein loading with coomassie blue of tissue and BALF protein  
828 homogenates (20  $\mu$ g loading for tissue, 7  $\mu$ g for BALF). Each lane represents a different mouse.  
829 **C,D)** Technical replicate assessment of  $\text{Log}_2$  MS/MS intensities from mouse BALF. **E,F)**  
830 Biological replicate assessment of  $\text{Log}_2$  MS/MS intensities from mouse BALF. Deviations from  
831 the plot origin indicate variability (C,E). Red line indicates linear goodness of fit (D,F).

Figure 1






Figure 2

**A**



**B**



**C**




Figure 2...continued




Figure 3





Figure 3...continued

**D**



**E**




Figure 4




Figure 5

